Literature DB >> 1646086

Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.

I Bourgault1, A Gomez, E Gomard, J P Levy.   

Abstract

Human Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTL) play an important role in maintaining the virus/host equilibrium during persistent infections. We analysed precursors of anti-EBV CTL by the limiting-dilution technique. Seven healthy EBV-seropositive and two EBV-seronegative donors were tested. All the donors seropositive for EBV gave clear-cut positive results, and it was remarkable that the frequency of CTL precursors (CTLp) observed was much higher than that reported for other viruses. In contrast, in the seronegative donors the frequency of CTLp was undetectable. The CTLp were derived from the CD4-CD8+ population only, although EBV-specific CD4+ cytolytic T cell clones have been described. A study of the HLA restriction showed that some HLA-A or HLA-B antigens can function as preferential restricting molecules, but that CTLp restricted by the other HLA-A or HLA-B molecules also exist. However, the dominant population of CTL present in primary responses is sometimes different from that of long term cell lines established from the same donor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646086      PMCID: PMC1535418     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  A virus-specific CD4+ cell-mediated cytolytic activity revealed by CD8+ cell elimination regularly develops in uncloned human antiviral cell lines.

Authors:  I Bourgault; A Gomez; E Gomard; F Picard; J P Levy; E Gomrad
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

2.  Role of different lymphocyte subsets in human anti-viral T cell cultures.

Authors:  A Gomez; I Bourgault; E Gomard; F Picard; J P Levy
Journal:  Cell Immunol       Date:  1989-02       Impact factor: 4.868

3.  A study of functionally active amino acids involved in the interaction of HLA-A2 or HLA-A3 molecules with cytolytic T lymphocytes.

Authors:  F Healy; J Sire; E Gomard; H Yssel; B Jordan; J P Levy
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

4.  The kinetics of generation of influenza-specific cytotoxic T-lymphocyte precursor cells.

Authors:  J A Owen; K I Dudzik; L Klein; D R Dorer
Journal:  Cell Immunol       Date:  1988-01       Impact factor: 4.868

5.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

6.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.

Authors:  C Taswell
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  In vitro human cytotoxic T cell responses against influenza A virus can be induced and selected by synthetic peptides.

Authors:  F Martinon; E Gomard; C Hannoun; J P Lévy
Journal:  Eur J Immunol       Date:  1990-10       Impact factor: 5.532

8.  Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.

Authors:  S Torsteinsdottir; M G Masucci; B Ehlin-Henriksson; C Brautbar; H Ben Bassat; G Klein; E Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity.

Authors:  L K Borysiewicz; S Graham; J K Hickling; P D Mason; J G Sissons
Journal:  Eur J Immunol       Date:  1988-02       Impact factor: 5.532

10.  Limiting dilution analysis of memory cytotoxic T lymphocytes specific for individual influenza virus gene products.

Authors:  M Wysocka; J R Bennink
Journal:  Cell Immunol       Date:  1988-04-01       Impact factor: 4.868

View more
  16 in total

Review 1.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 2.  Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.

Authors:  T Haque; D H Crawford
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Immunotherapy for EBV-associated malignancies.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Paola Zanovello; Antonio Rosato
Journal:  Int J Hematol       Date:  2011-02-19       Impact factor: 2.490

4.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

5.  High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes.

Authors:  C M Posavad; D M Koelle; L Corey
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 6.  Detection and characterization of Epstein-Barr virus in clinical specimens.

Authors:  R F Ambinder; R B Mann
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

7.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Authors:  Ekaterina Doubrovina; Banu Oflaz-Sozmen; Susan E Prockop; Nancy A Kernan; Sara Abramson; Julie Teruya-Feldstein; Cyrus Hedvat; Joanne F Chou; Glenn Heller; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Diane George; Ann Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Andromachi Scaradavou; Trudy N Small; Ramzi Khalaf; James W Young; Richard J O'Reilly
Journal:  Blood       Date:  2011-12-02       Impact factor: 22.113

8.  Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.

Authors:  M Dalod; M Dupuis; J C Deschemin; D Sicard; D Salmon; J F Delfraissy; A Venet; M Sinet; J G Guillet
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

9.  Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes.

Authors:  I Bourgault; A Venet; J P Levy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection.

Authors:  S L Silins; S M Cross; K G Krauer; D J Moss; C W Schmidt; I S Misko
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.